BeOne Medicines (ONC) Operating Leases (2019 - 2026)

BeOne Medicines (ONC) has 8 years of Operating Leases data on file, last reported at $49.7 million in Q1 2026.

• Quarterly Operating Leases fell 9.52% year-over-year to $49.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.7 million (down 9.52% YoY) and the FY2025 annual result came in at $52.9 million, down 14.41% from the prior year.
• Operating Leases fell to $49.7 million in Q1 2026 per ONC's latest filing, from $52.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $61.9 million in Q4 2024 and bottomed at $17.7 million in Q1 2024.
• The 5-year median for Operating Leases is $41.9 million (2022), against an average of $42.1 million.
• The widest annual swing landed in 2024, when Operating Leases plunged 45.54%; it then surged 209.76% in 2025.
• Tracing ONC's Operating Leases over 5 years: stood at $58.6 million in 2022, then declined by 24.52% to $44.2 million in 2023, then jumped by 39.94% to $61.9 million in 2024, then fell by 14.41% to $52.9 million in 2025, then slipped by 6.18% to $49.7 million in 2026.
• Per Business Quant, the three latest ONC Operating Leases figures stand at $49.7 million (Q1 2026), $52.9 million (Q4 2025), and $51.4 million (Q3 2025).

Peer Comparison